Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
L-carnitine vs placebo in aluminum phosphide poisoning
IRCT20120215009014N606Phase 3Recruiting
- Sponsor
- Hamadan University of Medical Sciences
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Aluminium phosphide poisoning comparing L-carnitine supplementation with Placebo (2 arms). Primary endpoints: Oxidative stress parameters, Inflammatory parameters and 3 more. Started May 2026; status: recruiting.
02
Drugs
levocarnitine
03
Conditions
Aluminium phosphide poisoning
Beyond the preview
Go deeper on IRCT20120215009014N606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20120215009014N606.